Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study

Klaus F. Rabe, Tito Atienza, P. Magyar, Per Larsson, Carin Jorup, Umesh G. Lalloo

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

Background: The contributions of as-needed inhaled corticosteroids and long-acting β2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting β2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. Methods: We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 μg and 4·5 μg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0·4 mg), formoterol (4·5 μg), or budesonide-formoterol (160 μg and 4·5 μg). The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalisation, emergency room treatment, or both, or the need for oral steroids for 3 days or more. Findings: Time to first severe exacerbation was longer with as-needed budesonide-formoterol versus formoterol (p=0·0048; log-rank test) and with as-needed formoterol versus terbutaline (p=0·0051). The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide-formoterol, respectively (rate ratios budesonide-formoterol versus formoterol 0·67 [95% CI 0·56-0·80; p

Original languageEnglish
Pages (from-to)744-753
Number of pages10
JournalThe Lancet
Volume368
Issue number9537
DOIs
Publication statusPublished - Aug 26 2006

Fingerprint

Budesonide
Double-Blind Method
Asthma
Terbutaline
Therapeutics
Adrenal Cortex Hormones
Formoterol Fumarate
Emergency Treatment
Inhalation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations : a randomised controlled, double-blind study. / Rabe, Klaus F.; Atienza, Tito; Magyar, P.; Larsson, Per; Jorup, Carin; Lalloo, Umesh G.

In: The Lancet, Vol. 368, No. 9537, 26.08.2006, p. 744-753.

Research output: Contribution to journalArticle

Rabe, Klaus F. ; Atienza, Tito ; Magyar, P. ; Larsson, Per ; Jorup, Carin ; Lalloo, Umesh G. / Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations : a randomised controlled, double-blind study. In: The Lancet. 2006 ; Vol. 368, No. 9537. pp. 744-753.
@article{2e0f0aa1101a4d85985cec241d63087a,
title = "Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study",
abstract = "Background: The contributions of as-needed inhaled corticosteroids and long-acting β2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting β2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. Methods: We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 μg and 4·5 μg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0·4 mg), formoterol (4·5 μg), or budesonide-formoterol (160 μg and 4·5 μg). The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalisation, emergency room treatment, or both, or the need for oral steroids for 3 days or more. Findings: Time to first severe exacerbation was longer with as-needed budesonide-formoterol versus formoterol (p=0·0048; log-rank test) and with as-needed formoterol versus terbutaline (p=0·0051). The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide-formoterol, respectively (rate ratios budesonide-formoterol versus formoterol 0·67 [95{\%} CI 0·56-0·80; p",
author = "Rabe, {Klaus F.} and Tito Atienza and P. Magyar and Per Larsson and Carin Jorup and Lalloo, {Umesh G.}",
year = "2006",
month = "8",
day = "26",
doi = "10.1016/S0140-6736(06)69284-2",
language = "English",
volume = "368",
pages = "744--753",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9537",

}

TY - JOUR

T1 - Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations

T2 - a randomised controlled, double-blind study

AU - Rabe, Klaus F.

AU - Atienza, Tito

AU - Magyar, P.

AU - Larsson, Per

AU - Jorup, Carin

AU - Lalloo, Umesh G.

PY - 2006/8/26

Y1 - 2006/8/26

N2 - Background: The contributions of as-needed inhaled corticosteroids and long-acting β2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting β2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. Methods: We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 μg and 4·5 μg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0·4 mg), formoterol (4·5 μg), or budesonide-formoterol (160 μg and 4·5 μg). The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalisation, emergency room treatment, or both, or the need for oral steroids for 3 days or more. Findings: Time to first severe exacerbation was longer with as-needed budesonide-formoterol versus formoterol (p=0·0048; log-rank test) and with as-needed formoterol versus terbutaline (p=0·0051). The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide-formoterol, respectively (rate ratios budesonide-formoterol versus formoterol 0·67 [95% CI 0·56-0·80; p

AB - Background: The contributions of as-needed inhaled corticosteroids and long-acting β2 agonists (LABA) to asthma control have not been fully established. We compared the efficacy and safety of three reliever strategies: a traditional short-acting β2 agonist; a rapid-onset LABA (formoterol); and a combination of LABA and an inhaled corticosteroid (budesonide-formoterol) in symptomatic patients receiving budesonide-formoterol maintenance therapy. Methods: We did a 12-month, double-blind, parallel-group study in 3394 patients (aged 12 years or older), in 289 centres in 20 countries, who were using inhaled corticosteroids at study entry and symptomatic on budesonide-formoterol (160 μg and 4·5 μg, respectively), one inhalation twice daily, during a 2-week run-in. After run-in, patients were randomly assigned budesonide-formoterol maintenance therapy plus one of three alternative as-needed medications-terbutaline (0·4 mg), formoterol (4·5 μg), or budesonide-formoterol (160 μg and 4·5 μg). The primary outcome was time to first severe exacerbation, defined as an event resulting in hospitalisation, emergency room treatment, or both, or the need for oral steroids for 3 days or more. Findings: Time to first severe exacerbation was longer with as-needed budesonide-formoterol versus formoterol (p=0·0048; log-rank test) and with as-needed formoterol versus terbutaline (p=0·0051). The rate of severe exacerbations was 37, 29, and 19 per 100 patients per year with as-needed terbutaline, formoterol, and budesonide-formoterol, respectively (rate ratios budesonide-formoterol versus formoterol 0·67 [95% CI 0·56-0·80; p

UR - http://www.scopus.com/inward/record.url?scp=33747761653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747761653&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(06)69284-2

DO - 10.1016/S0140-6736(06)69284-2

M3 - Article

C2 - 16935685

AN - SCOPUS:33747761653

VL - 368

SP - 744

EP - 753

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9537

ER -